Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ezrin negativity predicts poor prognosis in clear cell RCC

Key clinical point: Lack of ezrin protein expression was an independent predictor of poor prognosis in clear cell RCC.

Major finding: Patients whose tumors were immunohistochemically negative for ezrin had poorer disease-specific survival (HR for events, 1.89; 95% CI, 1.11-3.20).

Study details: Single-center retrospective cohort study of 575 consecutive patients surgically treated for clear cell RCC during 1985-2016.

Disclosures: Dr. Ferrari disclosed that he had no relevant conflicts of interest. The study did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sector.


Ferrari MVO et al. Urol Oncol. 2019 Oct 22. doi: 10.1016/j.urolonc.2019.09.011.